Yes, depending on the trial design and their agreement with FDA. Because STS phase I to III have already demonstrated safety, effectiveness and superiority to Dox and other treatments. SCLC phase II would be enough to prove the drug works effectively for approval on that indication. They may not need to go through another phase 3 unless they want to compare with other treatments. I thought I read about this somewhere but I can't remember. Therefore, if a deal was being made, SCLC results matters a lot.
ABBA might be hitting a home run here sitting on that many shares.
Market Data 
Markets 
AI
